AnGes saw the highest growth of 1.32% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.81% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of AnGes‘s patent filings and grants. Buy the databook here.
AnGes has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with ten publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 43% of filings. The World Intellectual Property Organization(WIPO), United States(US), European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where AnGes is filings its patents. Among the top granted patent authorities, AnGes has 100% of its grants in United States(US).
Regeneron Pharmaceuticals and Massachusetts Institute of Technology could be the strongest competitors for AnGes
Patents related to cell & gene therapy and genomics lead AnGes's portfolio
AnGes has the highest number of patents in cell & gene therapy followed by, genomics and immuno-oncology. For cell & gene therapy, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Parkinson's disease related patents lead AnGes portfolio followed by alzheimer's disease, and addictive disorders
AnGes has highest number of patents in parkinson's disease followed by alzheimer's disease, addictive disorders, schizophrenia, and fragile x syndrome.
For comprehensive analysis of AnGes's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.